Literature DB >> 16193252

Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy.

G M Galeazzi1, S Ferrari, G Giaroli, A Mackinnon, E Merelli, L Motti, M Rigatelli.   

Abstract

Associations between psychopathology and gender, duration of MS, disability and therapy with beta-interferons were studied in multiple sclerosis (MS) outpatients. A controlled descriptive epidemiological study was carried out in two Italian outpatient MS centres on 50 outpatients with clinically definite relapsing-remitting MS presenting for regular follow-up and 50 healthy controls matched for sex, age and educational level. Subjects were assessed with the Structured Clinical Interview for DSM-IV (SCID I), the Beck Depression Inventory (BDI) and the State Trait Anxiety Inventory (STAI). MS patients reported a higher prevalence of psychiatric disorders (odds ratio 3.17), with 46% (n=23) suffering from major depressive disorder. The risk of suffering from any non-mood psychiatric disorder was also higher in MS patients than in controls (odds ratio 2.67). Risk factors for depression were female sex and severity of disability, but not therapy with interferon beta or longer duration of illness. Disability level, but not therapy with beta-interferons, is a risk factor for depression in MS outpatients. Regular screening for depression in this population is appropriate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16193252     DOI: 10.1007/s10072-005-0468-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  26 in total

1.  Depression in multiple sclerosis: a longitudinal analysis.

Authors:  Claudia C Beal; Alexa K Stuifbergen; Adama Brown
Journal:  Arch Psychiatr Nurs       Date:  2007-08       Impact factor: 2.218

2.  Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.

Authors:  Irit Gil-Ad; Ben H Amit; Liat Hayardeni; Igor Tarasenko; Michal Taler; Ravit Uzan Gueta; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2014-07-27       Impact factor: 3.444

3.  Depression levels and interferon treatment in people with multiple sclerosis.

Authors:  Sonya Kim; Frederick W Foley; Mary Ann Picone; June Halper; Vance Zemon
Journal:  Int J MS Care       Date:  2012

4.  Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.

Authors:  Qianqian Wei; Zhenzhen Zheng; Xiaoyan Guo; Ruwei Ou; Xueping Chen; Rui Huang; Jing Yang; Huifang Shang
Journal:  Neurol Sci       Date:  2016-01-13       Impact factor: 3.307

5.  Progressive multiple sclerosis and mood disorders.

Authors:  Lorena Lorefice; G Fenu; G Trincas; M F Moro; J Frau; G C Coghe; E Cocco; M G Marrosu; M G Carta
Journal:  Neurol Sci       Date:  2015-04-22       Impact factor: 3.307

Review 6.  Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.

Authors:  Anja Kurt; Femke Nijboer; Tamara Matuz; Andrea Kübler
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis.

Authors:  Robert K McNamara; Therese Rider; Ronald Jandacek; Patrick Tso
Journal:  Psychiatry Res       Date:  2014-01-02       Impact factor: 3.222

8.  Depression and quality of life in patients with amyotrophic lateral sclerosis.

Authors:  Dorothée Lulé; Sonja Häcker; Albert Ludolph; Niels Birbaumer; Andrea Kübler
Journal:  Dtsch Arztebl Int       Date:  2008-06-06       Impact factor: 5.594

9.  Routine depression screening in an MS clinic and its association with provider treatment recommendations and related treatment outcome.

Authors:  L M Stepleman; L M Penwell-Waines; M Rollock; R S Casillas; T Brands; J Campbell; B Ange; J L Waller
Journal:  J Clin Psychol Med Settings       Date:  2014-12

10.  Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis.

Authors:  Benedetta Goretti; Emilio Portaccio; Valentina Zipoli; Bahia Hakiki; Gianfranco Siracusa; Sandro Sorbi; Maria Pia Amato
Journal:  Neurol Sci       Date:  2009-01-20       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.